Recent Quotes (30 days)

You have no recent quotes
chg | %

GeneNews Limited  

(Public, TSE:GEN)   Watch this stock  
Find more results for GEN
1.33
+0.02 (1.53%)
Sep 16 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.31 - 1.33
52 week 0.34 - 1.69
Open 1.32
Vol / Avg. 15,966.00/8,724.00
Mkt cap 67.84M
P/E     -
Div/yield     -
EPS -0.28
Shares 51.01M
Beta 1.28
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -614.17% -7120.15%
Operating margin -614.52% -7156.94%
EBITD margin - -4337.85%
Return on average assets -761.33% -142.79%
Return on average equity - -272.65%
Employees 4 -
CDP Score - -

Address

445 Apple Creed Blvd., Suite 220
RICHMOND HILL, ON L3R 9X7
Canada
+1-905-7392030 (Phone)
+1-905-7392031 (Fax)

Website links

Description

GeneNews Limited (GeneNews) is a molecular diagnostics company. The Company is focused on the application of functional genomics to enable early diagnosis and personalized health management. The Company�s Sentinel Principle detects and stages virtually any disease or medical condition from a simple blood sample. GeneNews is applies the Sentinel Principle in areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. Its ColonSentry product is used to determine an individual�s risk for colorectal cancer. During the year ended December 31, 2011, the Company announced the launch of ColonSentry in Malaysia. On February 21, 2012, the Company announced that its United States marketing partner, Enzo Clinical Labs Inc, had received clearance from the New York State Department of Health to perform, market and sell the ColonSentry test as a clinical laboratory service.

Officers and directors

James R. Howard-Tripp Executive Chairman of the Board
Leslie Auld Chief Financial Officer, Treasurer, Director
Karl Wassmann Executive Vice President - US Corporate Development
Heiner Dreismann Ph.D. Lead Director
Floyd C. Dent Director
Harry A. Glorikian Independent Director
Garth A. C. MacRae Independent Director
Age: 80
Rory B. Riggs Independent Director
Age: 48